Mantle cell lymphoma (MCL) is a rare and often aggressive subtype of non-Hodgkin lymphoma (NHL). It develops when B lymphocytes on the outer ring of a lymph node — the “mantle zone” — begin to grow and divide quickly and abnormally.
MCL is usually aggressive and spreads quickly, with 70% of patients in stage IV by the time they are diagnosed. This type of cancer responds well to chemotherapy, although relapse is not uncommon. Other treatment options include immunotherapy, stem cell transplant and radiation. The U.S. Food and Drug Administration (FDA) recently approved CAR T-cell therapy for patients with MCL who have not responded to or have relapsed following treatment, and ongoing clinical trials are leading to promising new advancements.
Although rare, some patients will develop a less aggressive version of the disease known as indolent or smoldering MCL, which progresses slowly and may not need to be treated immediately.
To learn more about mantle cell lymphoma, navigate to "What Is Mantle Cell Lymphoma?"